Hatchtech inks $279m head lice deal as VC market comes to life
14 September 2015
Posted in — OneVentures
Australian pharmaceutical company Hatchtech has inked a deal worth up to $279 million with Indian giant Dr. Reddy’s for the commercialisation of its innovative head lice treatment.
Author
Abbie Lewis
Abbie plays a key role in delivering OneVentures’ marketing, PR, community and branding initiatives, strengthening the firm’s identity and amplifying the visibility of our portfolio companies. Before joining OneVentures, Abbie worked at 89up in London, Europe’s first impact PR agency, where she contributed to global campaigns for NGOs.